9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma

Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma

Estimated reading time: < 1 min

Condition: Malignant Pleural Mesothelioma

Estimated Enrollment: 36

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Disease Control Rate (DCR),  Overall Survival (OS),  Progression Free Survival (PFS), Occurrence of Treatment Related Toxicity

Interventions: Cisplatin, Methotrexate

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: December 2019

Completion Date: December 2020

Last  Posted Date: August 7, 2019

Location: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Website Link: https://ClinicalTrials.gov/show/NCT02611037

Was this article helpful?
Dislike 0